Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.
View HTML
Toggle Summary ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass. --(BUSINESS WIRE)--May 29, 2020-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 20, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
View HTML
Toggle Summary ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting
Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs)
View HTML
Toggle Summary ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
Combination Demonstrates Promising Anti-Tumor Activity and Favorable Tolerability, with a Confirmed Overall Response Rate of >60% in Patients with High FRα Expression Results to be Presented in an Oral Session at ASCO 2020 Virtual Scientific Program WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 6, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 30, 2020 the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results
Pivotal SORAYA Trial Initiated for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer Data from FORWARD II Avastin ® Expansion Cohort in Platinum-Agnostic Ovarian Cancer Selected for Oral Presentation at ASCO Pre-Clinical Data on Next Generation Anti-FRα ADC to be Presented at AACR
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2020 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and 2019 Financial Results
Accelerated Approval Pathway Defined for Mirvetuximab Soravtansine in Ovarian Cancer; Pivotal SORAYA Trial Expected to Enroll First Patient in Q1 2020 Phase 3 Confirmatory MIRASOL Trial for Mirvetuximab Enrolling Patients Updated IMGN632 AML and BPDCN Monotherapy Data Presented at ASH $97.6 Million
View HTML